Zevra Therapeutics (ZVRA) EPS (Diluted) Growth (1y) (2016 - 2026)
Powered by 
Analysis
Zevra Therapeutics (ZVRA) EPS (Diluted) Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.89% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 144.25% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 315.14% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -11.18% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 96.41% |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | -89.24% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -89.24% |
| Mar 31, 2026 | 1,198.13% |
| Dec 31, 2025 | 127.49% |
| Sep 30, 2025 | 98.60% |
| Jun 30, 2025 | 378.91% |
| Mar 31, 2025 | 79.48% |
| Dec 31, 2024 | -131.26% |
| Sep 30, 2024 | -299.08% |
| Jun 30, 2024 | -1,000.30% |
| Mar 31, 2024 | -41.26% |
| Dec 31, 2023 | -120.51% |
| Sep 30, 2023 | -56.70% |
| Jun 30, 2023 | 89.30% |
| Mar 31, 2023 | -531.28% |
| Dec 31, 2022 | -233.74% |
| Sep 30, 2022 | -345.01% |
| Jun 30, 2022 | -120.33% |
| Mar 31, 2022 | 99.48% |
| Dec 31, 2021 | 92.56% |
| Sep 30, 2021 | 92.65% |